AbbVie Inc. $ABBV Shares Purchased by Elyxium Wealth LLC

Key Points

• Elyxium Wealth increased its AbbVie position by 1,108.7% in the second quarter, adding 44,291 shares to own 48,286 shares worth approximately $12.15 million. Institutional investors collectively hold 70.23% of AbbVie’s stock.
• AbbVie reported quarterly earnings and revenue above expectations, with EPS of $3.65 and revenue of $16.99 billion, up 10.2% year over year. The company guided for third-quarter EPS of $3.84–$3.88 and pays an annualized dividend of $6.92 per share.
• Analysts remain broadly positive, giving AbbVie a consensus “Moderate Buy” rating and an average price target of $275.95. Growth prospects include oncology and aesthetics pipeline programs, while an early-ended emraclidine study and a $8.18 million executive share sale present potential concerns.

Elyxium Wealth LLC increased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 1,108.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,286 shares of the company's stock after purchasing an additional 44,291 shares during the quarter. AbbVie accounts for about 1.3% of Elyxium Wealth LLC's holdings, making the stock its 15th largest holding. Elyxium Wealth LLC's holdings in AbbVie were worth $12,151,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock worth $3,056,000 after buying an additional 789 shares in the last quarter. Ieq Capital LLC lifted its stake in shares of AbbVie by 4.6% in the second quarter. Ieq Capital LLC now owns 120,035 shares of the company's stock worth $22,281,000 after buying an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC lifted its stake in shares of AbbVie by 117.3% in the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company's stock worth $210,685,000 after buying an additional 612,702 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ABBV shares. Barclays raised their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Citigroup increased their price target on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. Erste Group Bank upgraded AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. boosted their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Finally, BMO Capital Markets upped their target price on AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $275.95.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.

AbbVie Trading Up 1.4%

Shares of AbbVie stock opened at $265.62 on Friday. The company has a fifty day simple moving average of $248.48 and a 200-day simple moving average of $227.49. The stock has a market cap of $469.29 billion, a price-to-earnings ratio of 75.03, a PEG ratio of 0.87 and a beta of 0.30. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie's dividend payout ratio is 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source